Biotech news
Asia
Law firm Miller, Canfield, Paddock & Stone has expanded its IP team in China with the appointment of life sciences specialist Kening Li. 24 September 2014
Biotech
UK-based cancer drug company Sareum has been granted a patent for an invention forming part of its treatment methods. 22 September 2014
Asia
Biopharmaceutical company Epirus has said that India’s drug regulator has approved a biosimilar application to produce a version of a popular arthritis treatment drug. 16 September 2014
Pharma
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch. 4 September 2014
Americas
The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid. 22 August 2014
Americas
PhRMA has voiced concerns about the FDA’s draft guidance on biosimilars, which it suggests if enacted, could have an impact on the safety of biosimilar products. 15 August 2014
Americas
A group of 12 international biotechnology associations has written to the US Patent and Trademark Office (USPTO), raising concerns about the office’s guidelines on determining the patent eligibility of natural products in the aftermath of the Myriad and Mayo cases. 13 August 2014
Americas
South Korean biopharmaceutical company Celltrion has applied for approval from the US Food and Drug Administration (FDA) to market a biosimilar version of Remicade (infliximab), it announced yesterday (August 11). 12 August 2014
Americas
French pharmaceutical company Sanofi and the US-based MannKind Corporation have entered into an exclusive licensing agreement to develop and commercialise MannKind’s Afrezza (insulin human), an inhalable insulin therapy for adults with types 1 and 2 diabetes. 12 August 2014
Americas
The US Food and Drug Administration (FDA) has issued guidance for biological drug makers about what information they should provide the agency to determine when their products’ marketing exclusivity period should begin, known as the “date of first licensure”. 8 August 2014